Microbes and the Role of Antibiotic Treatment for Wheezy Lower Respiratory Tract Illnesses in Preschool Children

Allergies and the Environment (M Hernandez, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Allergies and the Environment

Abstract

Purpose of Review

Antibiotics are commonly used to treat wheezy lower respiratory tract illnesses in preschoolers, although these infections have been traditionally thought to be predominantly of viral origin. Our purpose is to review recent research pertaining to the role of antibiotics in lower respiratory tract illnesses and on subsequent asthma development, as well as the possible mechanisms of their effects.

Recent Findings

Increasing evidence suggests that asthma pathogenesis is associated with events during infancy and early childhood, particularly respiratory tract infections. While viruses are frequently detected in children with lower respiratory tract infections, the presence of potentially pathogenic bacteria is also often detected and may play a role in asthma pathogenesis. Recent evidence suggests that use of macrolides, particularly azithromycin, may decrease the risk of and duration of lower respiratory tract illnesses and prevent future episodes in specific high-risk populations.

Summary

Infants and preschoolers who have wheezy lower respiratory tract illnesses have a higher risk of asthma development. Alterations in the microbiome are thought to be influential. While several recent studies identify azithromycin as a therapeutic option in these illnesses, additional research is needed.

Keywords

Recurrent wheezing Bronchiolitis Asthma pathogenesis Antibiotics Macrolides Preschool children 

Notes

Compliance with Ethical Standards

Conflict of Interest

Dr. Kwong has nothing to disclose. Dr. Bacharier reports grant support from NIH; serving as a consultant to Aerocrine, GlaxoSmithKline, Genentech/Novartis, Cephalon, Teva, Circassia, and Boehringer Ingelheim; serving on advisory boards for Merck, Sanofi, and Vectura; serving on data and safety monitoring boards for DBV Technologies; and receiving honoraria for lectures or continuing medical education development from Aerocrine, GlaxoSmithKline, Genentech/Novartis, Merck, Cephalon, Teva, AstraZeneca, WebMD/Medscape, and Boehringer Ingelheim.

Human and Animal Rights and Informed Consent

All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Declaration of Helsinki and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).

References

Papers of Particular Interest, Published Recently, Have Been Highlighted as: • Of importance •• Of major importance

  1. 1.
    Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ. Asthma and wheezing in the first six years of life. N Engl J Med. 1995;332:133–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Moorman J, Akinbami L, Bailey C. National surveillance of asthma: United States, 2001–2010. Vital Heal Stat. 2012;3(35):1–67.Google Scholar
  3. 3.
    Teo SM, Mok D, Pham K, et al. The infant nasopharyngeal microbiome impacts severity of lower respiratory infection and risk of asthma development. Cell Host Microbe. 2015;17:704–15.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Sullivan A, Hunt E, MacSharry J, Murphy DM. The microbiome and the pathophysiology of asthma. Respir Res. 2016;17:163.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980–1996. JAMA. 1999;282:1440–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360:588–98.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Kusel MMH, de Klerk NH, Kebadze T, Vohma V, Holt PG, Johnston SL, et al. Early-life respiratory viral infections, atopic sensitization, and risk of subsequent development of persistent asthma. J Allergy Clin Immunol. 2007;119:1105–10.CrossRefPubMedGoogle Scholar
  8. 8.
    Jackson DJ, Evans MD, Gangnon RE, Tisler CJ, Pappas TE, Lee WM, et al. Evidence for a causal relationship between allergic sensitization and rhinovirus wheezing in early life. Am J Respir Crit Care Med. 2012;185:281–5.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Jackson DJ, Gangnon RE, Evans MD, et al. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am J Respir Crit Care Med. 2008;178:667–72.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Guilbert TW, Singh AM, Danov Z, et al. Decreased lung function after preschool wheezing rhinovirus illnesses in children at risk to develop asthma. J Allergy Clin Immunol. 2011;128:532–538.e10.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Bochkov YA, Watters K, Ashraf S, Griggs TF, Devries MK, Jackson DJ, et al. Cadherin-related family member 3, a childhood asthma susceptibility gene product, mediates rhinovirus C binding and replication. Proc Natl Acad Sci U S A. 2015;112:5485–90.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Drysdale SB, Alcazar M, Wilson T, et al. Respiratory outcome of prematurely born infants following human rhinovirus A and C infections. Eur J Pediatr. 2014;173:913–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Miller EK, Khuri-bulos N, Williams JV, et al. Human rhinovirus C associated with wheezing in hospitalized children in the Middle East. J Clin Virol. 2009;46:85–9.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. 1986;140:543–6.PubMedGoogle Scholar
  15. 15.
    Stein RT, Sherrill D, Morgan WJ, Holberg CJ, Halonen M, Taussig LM, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet. 1999;354:541–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Escobar GJ, Masaquel AS, Li SX, Walsh EM, Kipnis P. Persistent recurring wheezing in the fifth year of life after laboratory-confirmed, medically attended respiratory syncytial virus infection in infancy. BMC Pediatr. 2013;13:97.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Carroll KN, Wu P, Gebretsadik T, Griffin MR, Dupont WD, Mitchel EF, et al. The severity-dependent relationship of infant bronchiolitis on the risk and morbidity of early childhood asthma. J Allergy Clin Immunol. 2009;123:1055–1061.e1.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med. 2000;161:1501–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Bacharier LB, Cohen R, Schweiger T, Yin-Declue H, Christie C, Zheng J, et al. Determinants of asthma after severe respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol. 2012;130:91–100.e3.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Bertrand P, Lay MK, Piedimonte G, Brockmann PE, Palavecino CE, Hernández J, et al. Elevated IL-3 and IL-12p40 levels in the lower airway of infants with RSV-induced bronchiolitis correlate with recurrent wheezing. Cytokine. 2015;76:417–23.CrossRefPubMedGoogle Scholar
  21. 21.
    Torgerson DG, Giri T, Druley TE, et al. Pooled sequencing of candidate genes implicates rare variants in the development of asthma following severe RSV bronchiolitis in infancy. PLoS One. 2015;10:1–15.CrossRefGoogle Scholar
  22. 22.
    Nuolivirta K, Tormanen S, Terasjarvi J, Vuononvirta J, Koponen P, Korppi M, et al. Post-bronchiolitis wheezing is associated with toll-like receptor 9 rs187084 gene polymorphism. Sci Rep. 2016;6:1–9.CrossRefGoogle Scholar
  23. 23.
    Suárez-Arrabal MC, Mella C, Lopez SM, et al. Nasopharyngeal bacterial burden and antibiotics: influence on inflammatory markers and disease severity in infants with respiratory syncytial virus bronchiolitis. J Inf Secur. 2015;71:458–69.Google Scholar
  24. 24.
    • Carlsson CJ, Vissing NH, Sevelsted A, Johnston SL, Bonnelykke K, Bisgaard H. Duration of wheezy episodes in early childhood is independent of the microbial trigger. J Allergy Clin Immunol. 2015;136:1208–14. A large prospective cohort study of infants at high-risk for asthma. Nasopharyngeal and hypopharyngeal aspirates were obtained during acute wheezy episodes. Duration of wheezy episodes was found to be independent of the presence of potentially pathogenic bacteria or viruses CrossRefPubMedGoogle Scholar
  25. 25.
    Bisgaard H, Hermansen MN, Buchvald F, et al. Childhood asthma after bacterial colonization of the airway in neonates. N Engl J Med. 2007;357:1487–95.CrossRefPubMedGoogle Scholar
  26. 26.
    De Schutter I, Dreesman A, Soetens O, De Waele M, Crokaert F, Verhaegen J, et al. In young children, persistent wheezing is associated with bronchial bacterial infection: a retrospective analysis. BMC Pediatr. 2012;12:83.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Lynch SV, Wood RA, Boushey H, et al. Effects of early-life exposure to allergens and bacteria on recurrent wheeze and atopy in urban children. J Allergy Clin Immunol. 2014;134:593–601.e12.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Ege MJ, Mayer M, Normand A-C, Genuneit J, Cookson W, Braun-Fahrlander CB, et al. Exposure to environmental microorganisms and childhood asthma. N Engl J Med. 2011;364:701–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Stein MM, Hrusch CL, Gozdz J, et al. Innate immunity and asthma risk in Amish and Hutterite farm children. N Engl J Med. 2016;375:411–21.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Cardenas PA, Cooper PJ, Cox MJ, Chico M, Arias C, Moffatt MF, et al. Upper airways microbiota in antibiotic-naïve wheezing and healthy infants from the tropics of rural Ecuador. PLoS One. 2012; doi:10.1371/journal.pone.0046803.Google Scholar
  31. 31.
    •• Arrieta M-C, Stiemsma LT, Dimitriu PA, et al. Early infancy microbial and metabolic alterations affect risk of childhood asthma. Sci Transl Med. 2015;7:307ra152-307ra152. Analysis of the gut microbiome of 319 infants showed that a transient decrease in certain gut bacteria was associated with increased asthma risk CrossRefGoogle Scholar
  32. 32.
    Abrahamsson TR, Jakobsson HE, Andersson AF, Björkstén B, Engstrand L, Jenmalm MC. Low gut microbiota diversity in early infancy precedes asthma at school age. Clin Exp Allergy. 2014;44:842–50.CrossRefPubMedGoogle Scholar
  33. 33.
    Johnson LW, Robles J, Hudgins A, Osburn S, Martin D, Thompson A. Management of bronchiolitis in the emergency department: impact of evidence-based guidelines? Pediatrics. 2013;131:S103–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Farley R, Spurling GKP, Eriksson L, Del Mar CB. Antibiotics for bronchiolitis in children under two years of age (review). Cochrane Database Syst Rev. 2014:1–42.Google Scholar
  35. 35.
    • Ralston SL, Lieberthal A, Meissner HC, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis 2014. Pediatrics. 2014; doi:10.1542/peds.2014-2742. These are the current guidelines for bronchiolitis management Google Scholar
  36. 36.
    Lassi ZS, Kumar R, Das JK, Salam RA, Bhutta ZA. Antibiotic therapy versus no antibiotic therapy for children aged two to 59 months with WHO-defined non-severe pneumonia and wheeze. Cochrane Database Syst Rev. 2014;5:CD009576.Google Scholar
  37. 37.
    McCallum GB, Morris PS, Chang AB. Antibiotics for persistent cough or wheeze following acute bronchiolitis in children. Cochrane Database Syst Rev. 2012;12:CD009834.PubMedGoogle Scholar
  38. 38.
    Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med. 2008;177:148–55.CrossRefPubMedGoogle Scholar
  39. 39.
    Cameron EJ, Mcsharry C, Chaudhuri R, Farrow S, Thomson NC. Long-term macrolide treatment of chronic inflammatory airway diseases: risks, benefits and future developments. Clin Exp Allergy. 2012;42:1302–12.CrossRefPubMedGoogle Scholar
  40. 40.
    Kneyber MCJ, van Woensel JBM, Uijtendaal E, Uiterwaal CSPM, Kimpen JLL. Azithromycin does not improve disease course in hospitalized infants with respiratory syncytial virus (RSV) lower respiratory tract disease: a randomized equivalence trial. Pediatr Pulmonol. 2008;43:142–9.CrossRefPubMedGoogle Scholar
  41. 41.
    Pinto LA, Pitrez PM, Luisi F, et al. Azithromycin therapy in hospitalized infants with acute bronchiolitis is not associated with better clinical outcomes: a randomized, double-blinded, and placebo-controlled clinical trial. J Pediatr 2012;161:1104–8.Google Scholar
  42. 42.
    McCallum GB, Morris PS, Chatfield MD, Maclennan C, White AV, Sloots TP, et al. A single dose of azithromycin does not improve clinical outcomes of children hospitalised with bronchiolitis: a randomised, placebo-controlled trial. PLoS One. 2013;8:e74316.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    • McCallum GB, Morris PS, Grimwood K, et al. Three-weekly doses of azithromycin for indigenous infants hospitalized with bronchiolitis: a multicentre, randomized, placebo-controlled trial. Front Pediatr. 2015;3:32. Study of indigenous children from Australia and New Zealand with RSV assessing the effect of azithromycin use on their subsequent hospital course CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    •• Bacharier LB, Guilbert TW, Mauger DT, et al. Early administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses: a randomized clinical trial. JAMA. 2015;314:2034–44. Large multicenter trial demonstrating that the use of azithromycin at the beginning of a respiratory tract illness decreases the risk of progression to a severe episode in high risk children CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    •• Stokholm J, Chawes BL, Vissing NH, et al. Azithromycin for episodes with asthma-like symptoms in young children aged 1–3 years: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2016;4:19–26. Azithromycin use was associated with a reduced duration of asthma-like symptoms in children with a prior history of asthma-like symptoms, with the greatest reduction noted with early azithromycin initiation CrossRefPubMedGoogle Scholar
  46. 46.
    • Korpela K, Salonen A, Virta LJ, Kekkonen RA, Forslund K, Bork P, et al. Intestinal microbiome is related to lifetime antibiotic use in Finnish pre-school children. Nat Commun. 2016;7:10410. Study of Finnish children demonstrating that early-onset antibiotic use is associated with long-lasting alterations in the intestinal microbiome CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Ong MS, Umetsu DT, Mandl KD. Consequences of antibiotics and infections in infancy: bugs, drugs, and wheezing. Ann Allergy, Asthma Immunol. 2014;112:441–445.e1.CrossRefGoogle Scholar
  48. 48.
    Lee E, Kwon J-W, Kim H-B, et al. Association between antibiotic exposure, bronchiolitis, and TLR4 (rs1927911) polymorphisms in childhood asthma. Allergy Asthma Immunol Res. 2015;7:167–74.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Tahan F, Ozcan A, Koc N. Clarithromycin in the treatment of RSV bronchiolitis: a double-blind, randomised, placebo-controlled trial. Eur Respir J. 2007;29:91–7.CrossRefPubMedGoogle Scholar
  50. 50.
    Korrpi M. To the editors: macrolides and bronchiolitis in infants. Eur Respir J. 2007;29:1283–4.CrossRefGoogle Scholar
  51. 51.
    Tahan F. From the authors: macrolides and bronchiolitis in infants. Eur Respir J. 2007;29:1284.CrossRefGoogle Scholar
  52. 52.
    •• Beigelman A, Isaacson-Schmid M, Sajol G, et al. Randomized trial to evaluate azithromycin’s effects on serum and upper airway IL-8 levels and recurrent wheezing in infants with respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol. 2015;135:1171–1178e1. Proof-of-concept trial of otherwise healthy infants who were hospitalized for RSV bronchiolitis. Use of azithromycin was associated with a reduction in the risk of recurrent wheezing in the following year CrossRefPubMedGoogle Scholar
  53. 53.
    Beigelman A, Bacharier LB. Reply. J Allergy Clin Immunol. 2015; 136:1135–6.Google Scholar
  54. 54.
    Zhou Y, Bacharier LB, Isaacson-Schmid M, Baty J, Schechtman KB, Sajol G, et al. Azithromycin therapy during respiratory syncytial virus bronchiolitis: upper airway microbiome alterations and subsequent recurrent wheeze. J Allergy Clin Immunol. 2016;138:1215–1219.e5.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.Division of Allergy, Immunology and Pulmonary Medicine, Department of PediatricsWashington University School of Medicine in St. Louis, St. Louis Children’s HospitalSt. LouisUSA

Personalised recommendations